Premium
Cerebrovascular disease with antiphospholipid antibodies: Immune mechanisms, significance, and therapeutic options
Author(s) -
Feldmann Edward,
Levine Steven R.
Publication year - 1995
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.410370712
Subject(s) - medicine , immunology , antibody , antiphospholipid syndrome , coagulopathy , coagulation , lupus anticoagulant , immune system
There has been a recent, dramatic surge in interest in antiphospholipid antibodies and associated clinical disorders, especially focal ischemic cerebrovascular disease. Antiphospholipid antibodies are a heterogeneous group of antibodies with varying specificities. Coagulation assays will detect lupus anticoagulants while enzyme‐linked immunosorbent assays detect anticardiolipin antibodies. There are numerous potential links between antiphospholipid antibodies and coagulation disorders, including interaction of antiphospholipid antibodies and a cofactor, β 2 –glycoprotein I, which itself is involved in coagulation mechanisms. While the specific mechanism of antiphospholipid antibody‐related coagulopathy is unknown, it is clear that antiphospholipid antibodies are associated with an immune‐mediated prothrombotic state. Patients with the highest titers of IgG antiphospholipid antibodies have a relatively high risk of recurrent thrombotic events, especially stroke, deep venous thrombosis, and spontaneous abortion. Because of limited controlled, prospective data, current therapy remains empiric and directed at coagulation mechanisms, immune mechanisms, or both.